Drug niraparib benefits women newly diagnosed with advanced ovarian cancer
Researchers have discovered a drug named niraparib, can prove beneficial for women newly diagnosed with advanced ovarian cancer.
The study demonstrates that administering niraparib after conventional chemotherapy treatment in newly diagnosed patients, improves their progression-free survival and reduces their risk of relapse or death from this disease.
The study shows that administering niraparib reduces risk of relapse or death from this disease by nearly 40 %.
We evaluated the benefits of using niraparib after standard treatment of ovarian cancer based on chemotherapy after surgery. With this new therapeutic approach we've observed a significant improvement in patient progression-free survival and a reduction of almost 40 % of their risk of relapse, said the first author.
Ovarian cancer, diagnosed in around 205,000 women worldwide every year, is the 5th leading cause of cancer death in women in Europe.
It is usually diagnosed between 45 and 75 years, although there are a significant number of patients from 30 years. It is the gynecological tumour that causes more deaths because most patients are diagnosed in an advanced stage of the disease, given the absence of early diagnosis techniques.
The study analysed 733 newly diagnosed patients with advanced ovarian cancer ( with serious histological type, or endometrium of high grade).
The work consisted of adding niraparib after the conventional first-line chemotherapy treatment for these patients after surgery.
Niraparib is a potent PARP inhibitor drug ( an enzyme involved in DNA repair and cell death) that is used as maintenance therapy in women with ovarian cancer relapse, whether or not they've mutated the BRCA gene ( associated with the risk of suffering from this disease).
In turn, the effect of this treatment was studied in patients with a type of defect in DNA repair called homologous recombination deficiency (HRD).
In patients who did show this deficiency ( half of the women in the study), the benefit of treatment was even more significant, achieving a 57% reduction in the risk of relapse or disease progression.
The safety profile of the drug was similar to that observed in other trials with niraparib.
These findings " suggest considering niraparib as a first option treatment for patients with advanced ovarian cancer after completing first-line chemotherapy", said the Dr.
this is only for your information, kindly take the advice of your doctor for medicines, exercises and so on.
https://gscrochetdesigns.blogspot.com. one can see my crochet creations
https://gseasyrecipes.blogspot.com. feel free to view for easy, simple and healthy recipes
https://kneereplacement-stickclub.blogspot.com. for info on knee replacement
The study demonstrates that administering niraparib after conventional chemotherapy treatment in newly diagnosed patients, improves their progression-free survival and reduces their risk of relapse or death from this disease.
The study shows that administering niraparib reduces risk of relapse or death from this disease by nearly 40 %.
We evaluated the benefits of using niraparib after standard treatment of ovarian cancer based on chemotherapy after surgery. With this new therapeutic approach we've observed a significant improvement in patient progression-free survival and a reduction of almost 40 % of their risk of relapse, said the first author.
Ovarian cancer, diagnosed in around 205,000 women worldwide every year, is the 5th leading cause of cancer death in women in Europe.
It is usually diagnosed between 45 and 75 years, although there are a significant number of patients from 30 years. It is the gynecological tumour that causes more deaths because most patients are diagnosed in an advanced stage of the disease, given the absence of early diagnosis techniques.
The study analysed 733 newly diagnosed patients with advanced ovarian cancer ( with serious histological type, or endometrium of high grade).
The work consisted of adding niraparib after the conventional first-line chemotherapy treatment for these patients after surgery.
Niraparib is a potent PARP inhibitor drug ( an enzyme involved in DNA repair and cell death) that is used as maintenance therapy in women with ovarian cancer relapse, whether or not they've mutated the BRCA gene ( associated with the risk of suffering from this disease).
In turn, the effect of this treatment was studied in patients with a type of defect in DNA repair called homologous recombination deficiency (HRD).
In patients who did show this deficiency ( half of the women in the study), the benefit of treatment was even more significant, achieving a 57% reduction in the risk of relapse or disease progression.
The safety profile of the drug was similar to that observed in other trials with niraparib.
These findings " suggest considering niraparib as a first option treatment for patients with advanced ovarian cancer after completing first-line chemotherapy", said the Dr.
this is only for your information, kindly take the advice of your doctor for medicines, exercises and so on.
https://gscrochetdesigns.blogspot.com. one can see my crochet creations
https://gseasyrecipes.blogspot.com. feel free to view for easy, simple and healthy recipes
https://kneereplacement-stickclub.blogspot.com. for info on knee replacement
Labels: administered, beneficial, BRCA gene, chemotherapy, improves, new drug, newly diagnosed, niraparib, ovarian cancer, PARP inhibitors, progression-free survival, reduces risk of, relapse
posted by G S Iyer at 11:07 PM
0 Comments:
Post a Comment
<< Home